Trials / Completed
CompletedNCT00680992
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 535 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
To determine how safe denosumab is in treating subjects with giant cell tumor of bone (GCTB)
Detailed description
To determine how safe denosumab is in treating subjects with GCTB
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Denosumab | 120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15. |
Timeline
- Start date
- 2008-09-09
- Primary completion
- 2018-05-17
- Completion
- 2018-05-17
- First posted
- 2008-05-20
- Last updated
- 2022-09-22
- Results posted
- 2018-12-10
Locations
33 sites across 12 countries: United States, Australia, Austria, Canada, France, Germany, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00680992. Inclusion in this directory is not an endorsement.